| Nov 14 |
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline
|
| Nov 12 |
Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% in One Week: What You Should Know
|
| Nov 11 |
Poseida Therapeutics to Present at Two Upcoming Investor Conferences
|
| Nov 9 |
Poseida Therapeutics Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 8 |
Poseida Therapeutics GAAP EPS of $0.21, revenue of $71.7M
|
| Nov 7 |
Poseida Therapeutics, Inc. (PSTX) Q3 Earnings and Revenues Beat Estimates
|
| Nov 7 |
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024
|
| Nov 5 |
Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024
|
| Nov 5 |
Organogenesis Holdings And 2 Other US Penny Stocks To Watch
|
| Oct 24 |
Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema
|
